ABSTRACT
To evaluate the efficacy and safety of intracameral air injection in treating acute hydrops in Keratoconus. Twenty one [21 patients] with acute hydrops secondary to keratoconus. Nine eyes [nine patients] with acute hydrops in keratoconus were treated with intracameral injection of 0.1 ml filtered air. Additional 0.1 ml filtered air was injected if corneal edema persisted when air disappeared from the anterior chamber. Twelve eyes [12 patients] with acute hydrops, that received no therapy or conventional therapy not likely to shorten the duration of hydrops served as controls. Main outcome measures: The period of persistence of comeal edema, the interval between the onset of acute hydrops, and the time when the eye could begin to wear a hard-contact lens, and best spectacle corrected and hard-contact lens-corrected visual acuity after corneal edema subsided were used as criteria to evaluate any differences between the two groups. The average period of persistence of corneal edema was 22.1 +/- 8.0 days [ +/- SD] in the intracameral air injection group and 67.6 +/- 35.7 days in the control group [P =.0009]. The average interval between the onset of acute hydrops and the time when the eye could begin to wear a hard- contact lens, 32.8 +/- 5.7 days in the air injection group and 129.8 +/- 75.7 days in the control group [P =.0056]. The best-corrected visual acuity after corneal edema subsided was similar between the two groups. Intracameral air injection induced no complications. The results suggest that the intracameral air injection is a safe and useful therapy to shorten the period of corneal edema in acute hydrops secondary to kerateconus
Subject(s)
Humans , Male , Female , /therapy , Air , Injections , Corneal EdemaABSTRACT
To compare the effect pressure [IOP] of latanoprost monotherapy and timololpilocarpine in patients with glaucoma or oclular hypertension with inadequately controlled IOP on topical B adrenergic antagonists. This was randomized, observer masked, 6 weeks study performed on 112 patients with glaucoma or ocular hypertension and IOP of at least 22 mmHg on treatment with timolol 0.5 percent twice daily of at least 21 days. The patients were randomized into two parallel groups: either to latanoprost 0.005 percent once daily or to combination of timolol pilocarpine. Changes in mean diurnal IOP from baseline to the 6 week visit were determined. Switching from timolol 0.5 percent to latanoprost 0:005 percent once daily caused a statistically significant reduction in mean IOP [P < 0.001], and switching from timolol to timolol-pilocarpine twice daily caused a statistically significant reduction in mean diurnal IOP [P < 0.001].Latanoprost monotherapy was at least as effective as combination of timolol-pilocarpine twice daily treatment in reducing IOP in patients not adequately controlled on B adrenergic antagonists